Teva continues to see significant potential in complex generics in the US, with a number of opportunities in its pipeline and some high-value targets in its sights.
However, speaking to Generics Bulletin, Sven Dethlefs – Teva’s executive vice president for North America commercial – has outlined some of the challenges that the firm sees in bringing these products to market, in particular when it